

INDEPENDENT AUDITORS' REPORT

**To the Members of
Mono Pharmacare Limited**

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **Mono Pharmacare Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss and Cash Flow Statement for the year then ended and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of the other auditors on separate financial statements of such subsidiaries as were audited by the other auditors, the aforesaid financial statements give the information required by the Companies Act, 2013 in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Company as at 31st March, 2023 and its consolidated profit and its consolidated cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information Other than the Financial Statements and Auditor's Report Thereon



The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the consolidated financial statements and our Auditor's Report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to Report that fact. We have nothing to Report in this regard.

Responsibility of Management and Those Charge with Governance for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financials position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India including the other accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial Reporting process.




Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated




financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our Auditor's Report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our Report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit and on the consideration of the reports of separate financial statements of the subsidiary Company, we report to the extent applicable that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.



- e) On the basis of the written representations received from the directors as on March 31, 2023, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls with reference to consolidated financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure A" which is based on the auditors' reports of the Parent, subsidiary companies incorporated in India. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of internal financial controls with reference to consolidated financial statements of those companies.
- g) As per information and explanation given by the management, the internal financial controls reporting is not applicable to the Company as condition specified under section 143(3) of the Companies Act, 2013 are satisfied.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company has not entered any long-term contracts including derivative contracts for which there were any material foreseeable losses, as required under the applicable law or Indian Accounting Standards.
 - iii. There has been no delay in transferring the amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in or her persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;




(b) The Management has represented , that, to the best of its knowledge and belief, no funds have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding , whether recorded in writing or otherwise, that the Company shall, whether , directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries ") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11 (e), as provided under (a) and (b) above, contain any material misstatement.

v. The Company has not declared or paid any dividend during the year hence no compliance is required with Section 123 of the Companies Act 2013.

2. With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor's Report) Order, 2020 ("CARO"/ "the Order") issued by the Central Government in terms of Section 143(11) of the Act, according to the information and explanations given to us, and based on the CARO reports issued by us, we report that there are no qualifications or adverse remarks by the respective auditors in the CARO reports of the said companies included in the consolidated financial statements.



For **KUMBHAT & CO.**
Chartered Accountants
Firm Reg. No. 001609S

A handwritten signature in black ink, appearing to read "Gaurang C. Unadkat".

Gaurang C. Unadkat
Partner

Membership No. 131708

UDIN: 23131708BGWHGF6813

Place: Mumbai

Date: August 07th, 2023

MONO PHARMACARE LIMITED
Consolidated Balance Sheet as at March 31,2023
 CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

	Particulars	Note No.	As at March 31,2023
I.	EQUITY AND LIABILITIES		
(1)	Shareholders' Funds		
	(a) Share Capital	2	1236.86
	(b) Reserve and surplus	3	101.47
			0.69
(2)	Minority Interest		1339.01
(3)	Non-current liabilities		
	(a) Long-term borrowings	4	1801.04
			1801.04
(4)	Current Liabilities		
	(a) Short Term Borrowings	5	2248.74
	(b) Trade Payables	6	
	(i) Total outstanding dues of micro enterprises and small enterprises		583.28
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises		94.32
	(c) Other Current Liabilities	7	118.01
	(d) Short-term Provisions	8	75.85
			3120.20
	TOTAL		6260.25
II.	ASSETS		
(1)	Non Current Assets		
	(a) Property, Plants & Equipment	9	85.26
	(i) Tangible Assets		
	(c) Non-Current Investments	10	57.34
	(b) Deferred tax assets (Net)	11	5.49
			148.10
(2)	Current Assets		
	(a) Inventories	12	3268.61
	(b) Trade Receivables	13	2187.07
	(c) Cash and Cash Equivalents	14	41.77
	(d) Short Term Loans and Advances	15	535.37
	(e) Other Current Assets	16	79.32
			6112.15
	TOTAL		6260.25
	Significant Accounting Policies	1 2 - 34	

See accompanying annexures forming part of the financial statement

For Kumbhat & Co.
 Chartered Accountants
 FRN: 001609S

Gaurang Unadkat

Gaurang Unadkat
 Partner
 Membership No. : 131708
 Place:- Ahmedabad
 Date:- August 7th, 2023

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya
Panilam S. Lakhatariya
 Chairman & Managing Director
 DIN: 07659275

Neha C Prajapati
Neha C Prajapati
 Chief Financial Officer

A.S. Shah
A.S. Shah
 Archit Shah
 Director
 DIN: 09737945

Krupali Thakkar
Krupali Thakkar
 Company Secretary
 Place: Ahmedabad
 Date:- August 7th, 2023

MONO PHARMACARE LIMITED
Consolidated Statement of Profit and Loss for the year ended March 31, 2023
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

	Particulars	Note No.	From 06/12/2022 to 31/03/2023
I	Revenue from operation	17	2699.05
II	Other income	18	23.26
III	Total Revenue (I + II)		2722.31
IV	Expenses		
	Purchase of Traded Goods	19	3419.18
	(Increase)/Decrease in Stock	20	-1016.03
	Employee Benefits Expenses	21	78.17
	Finance Cost	22	77.10
	Depreciation and Amortisation Cost	9	4.74
	Other expenses	23	66.20
	Total Expenses		2629.36
V	Profit before tax Extraordinary and Exceptional Items (III - IV)		92.96
VI	Exceptional Items		0.00
VII	Extraordinary Items And Tax (V- VI)		
	Prior Period Expenses		0.00
VIII	Profit Before Tax		92.96
IX	Tax Expenses		
	(1) Current Tax		28.30
	(2) Deferred Tax		-5.49
X	Profit (Loss) for the Year		70.15
XI	Minority Interest		-0.18
XII	Profit/(Loss) for the year after Taxes and Minority Interest		69.97
XIII	Earning per Equity share :	30	
	(1) Basic		0.71
	(2) Diluted		0.71
	Significant Accounting Policies	1 2 - 34	

See accompanying annexures forming part of the financial statement

For Kumbhat & Co.

Chartered Accountants

FRN: 001609S



Gaurang Unadkat
Partner

Membership No. : 131708

Place:- Ahmedabad

Date:- August 7th, 2023

For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya
Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Neha C Prajapati
Neha C Prajapati
Chief Financial Officer

A. S. Shah

Archit Shah
Director
DIN: 09737945

Krupali Thakkar
Krupali Thakkar
Company Secretary

Place: Ahmedabad

Date:- August 7th, 2023

MONO PHARMACARE LIMITED
Consolidated Cash flow statement for the period ended 31st March 2023
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

March 31, 2023

Cash flow from operating activities	
Profit/(loss) before tax	92.96
Non-cash adjustments to reconcile profit before tax to net cash flows	
Depreciation	4.74
Finance Cost	77.10
Operating profit/(loss) before working capital changes	174.80
Movements in working capital:	
Increase/(decrease) in trade payables	677.60
Increase/(decrease) in other current liabilities	118.01
Increase/(decrease) in short term provision	75.85
Increase/(decrease) in short term borrowings	2248.74
Decrease/(increase) in Inventories	-3268.61
Decrease/(increase) in trade receivables	-2187.07
Decrease/(increase) in short-term loans and advances	-535.37
Decrease/(increase) in other Current Assets	-79.32
Cash generated from Operations	-2775.38
Less: Direct taxes paid	
Net Cash from Operating Activities (A)	-2775.38
Cash flows from investing activities	
Sale/(Purchase) of Fixed Assets	-86.30
Purchase of Investment	-57.34
Net cash flow from/(used in) investing activities (B)	-143.64
Cash flow from financing activities	
Acceptance / (Repayment) of Long Term Loan	1801.04
Acceptance / (Repayment) of Short Term Loan	
Increase in Share Capital	1236.86
Finance Cost	-77.10
Net cash flow from/(used in) financing activities (C)	2960.80
Net increase/(decrease) in cash and cash equivalents (A+B+C)	41.77
Cash and cash equivalents at the beginning of the year	0.00
Cash and cash equivalents at the end of the year	41.77
Net increase/(decrease) in cash and cash equivalents	41.77

See accompanying annexures forming part of the financial statement

For Kumbhat & Co.

Chartered Accountants

FRN: 001609S

Gaurang Unadkat


Gaurang Unadkat

Partner

Membership No. : 131708

Place:- Ahmedabad

Date:- August 7th, 2023



For and on behalf of the Board of Directors Mono Pharmacare Limited

Panilam S. Lakhatariya

Panilam S. Lakhatariya

Chairman & Managing Director

DIN: 07659275

Neha C Prajapati

Neha C Prajapati

Chief Financial Officer

A.S. Shah

Archit Shah

Director

DIN: 09737945

Krupali Thakkar

Krupali Thakkar

Company Secretary

Place: Ahmedabad

Date:- August 7th, 2023

MONO PHARMACARE LIMITED

Consolidated Notes On Financial Statements For The Year Ended 31st March, 2023

CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

Particulars	As at March 31, 2023
NOTE 2: STATEMENT OF SHARE CAPITAL	
Authorised Share Capital 2,00,00,000 Equity Shares of Rs. 10/- each.	2000.00
Issued Subscribed and paid up Share Capital 1,23,68,564 Equity Shares of Rs. 10/- each.	1236.86
Partners' Capital Account	1236.86

NOTE 2.1: Reconciliation of No. of shares Outstanding at the beginning & at the end of the reporting period

	As at March 31, 2023	
	No.	Rs.
At the beginning of the period	100,000	10.00
Add: Equity Shares issued during the period	4,313,650	431.37
Add: Preference Shares issued during the period	5,081,699	508.17
Add: Rights Shares issued during the period	2,345,695	234.57
Add: Bonus Shares issued during the period	527,520	52.75
Outstanding at the end of the year	12,368,564	1236.86

NOTE 2.2: The details of shareholders holding of more than 5% of the aggregate shares of the Company


Name of the Shareholders	As at March 31, 2023	
	No. of Shares held	%
Panilam Shivilal Lakhatariya (Promoter)	8,026,761	64.90%
Supal Panilam Lakhatariya (Promoter)	1,993,458	16.12%
Others	2,348,345	18.99%
Total	12,368,564	100.00%

Terms/Rights to Equity Shares

- (a) The company has only one class of shares i.e. Equity Share
 (b) All equity shares rank pari-pasu and carry equal right respect to voting and dividend. In the event of liquidation of the company the equity shares holder shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts

NOTE 3: STATEMENT OF RESERVES & SURPLUS

Security premium	48.88
Profit and Loss Account	
Opening balance	
Add : Profit during the period	52.59
Add : Minority Interest	0.29
Balance at the end of the year	101.76




MONO PHARMACARE LIMITED
Consolidated Notes On Financial Statements For The Year Ended 31st March, 2023
CIN: U24304GJ2022PLC136193

(Rupees in Lakhs)

Particulars		As at March 31, 2023
<u>NOTE 4: STATEMENT OF LONG-TERM BORROWINGS</u>		
<u>Secured Loan</u>		
<u>Working Capital Demand Loan</u>		
(a) From Banks		281.76
		281.76
<p>(The above includes loan taken from Bank of India and Deutsche Bank having interest rate on such loans are 8.75% and 7.10%, and those are repayable between period of 2-3 years and 15 Years respectively. The above loan is classified as Current and Non-current based on the original tenure of the loan.</p>		
<u>Unsecured Loan :</u>		
<u>Working Capital Demand Loan</u>		
(a) From Banks		13.32
(b) From Financial Institution		3.21
(b) From Related Parties		1502.75
		1801.04

(Unsecured Loan is taken from various Banks and Financial Institution and interest rate is between 18% to 20% which is repayable between period of 3 years to 15 years and the same has been classified as Current and Non-current based on the original tenure of the loan)



MONO PHARMACARE LIMITED

Consolidated Notes On Financial Statements For The Year Ended 31st March, 2023

CIN: U24304GJ2022PLC136193

(Rs in Lakhs)


Particulars	As at March 31, 2023
<u>NOTE 5 :- STATEMENT OF SHORT TERM BORROWINGS</u>	
<u>Secured Loan</u>	
<u>From Banks</u>	
(a) Cash Credit	2088.04
Bank of India: Secured against the hypothecation of Stock and Book Debts and Mortgage against the Residential flat No. B 703 and 704, and C- 603, Shyam Elegance, Anandnagar Cross Road, Vastrapur Railway Station Road, Jodhpur, Ahmedabad Pin 380015 owned Mrs. Supal Panilam Lakhtariya and Pledging of TDR in the name of Mr. Panilam Lakhatariya of Rs. 30.00 lacs	
Cosmos Bank: Hypothecation Charge on all current assets of firm and Mortgage of Immovable Property Residential flat No. C 701 and 702, Shyam Elegance, Mouje: Vejalpur, Ahmedabad and Secured against the Residential flat 403-B, Palmera, Vadsar, Vododara owned by Mr. Panilam Shivilal Lakhatriya.	
(b) Working Capital Demand Loan	
(The above includes loan taken from Bank of India and Deutsche Bank having interest rate on such loans are 8.75% and 7.10%, and those are repayable between period of 2-3 years and 15 Years respectively. The above loan is classified as Current and Non-current based on the original tenure of the loan.	38.45
<u>UnSecured Loan</u>	
<u>Working Capital Demand Loan</u>	
From Banks	59.10
From Financial Institution	63.15
(Unsecured Loan is taken from various Banks and Financial Institution and interest rate is between 18% to 20% which is repayable between period of 3 years to 15 years and the same has been classified as Current and Non-current based on the original tenure of the loan)	
	2248.74
<u>NOTE 6 :- STATEMENT OF TRADE PAYABLES</u>	
<u>For goods and Services</u>	
Total outstanding dues of micro enterprises and small enterprises	583.28
Total outstanding dues of creditors other than micro enterprises and small enterprises	94.32
Total	677.60



MONO PHARMACARE LIMITED
Consolidated Notes On Financial Statements For The Year Ended 31st March, 2023
CIN: U24304GJ2022PLC136193

(Rs in Lakhs)

Particulars	As at March 31, 2023
<u>NOTE 7 :- STATEMENT OF OTHER CURRENT LIABILITIES</u>	
<u>Other Current Liabilities</u>	
Audit fees Payable	0.50
Expenses Payable	13.89
Salary Payable	16.84
Rent Payable	1.77
Statutory dues Payable	10.32
Interest Payable	0.37
Advance recd from Customers	74.31
	118.01
<u>NOTE 8 :- STATEMENT OF SHORT TERM PROVISIONS</u>	
Provision for Gratuity	2.63
Provision for Tax (Net off)	73.22
Total	75.85



MONO PHARMACARE LIMITED


Consolidated Notes On Financial Statements For The Year Ended 31st March, 2023

NOTE: 9 STATEMENT OF PROPERTY, PLANT AND EQUIPMENT

CIN: U24304GJ2022PLC136193

(Rs. in lakhs)

PARTICULARS	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	AS ON 06/12/22	ADDITION	DEDUCTION	TOTAL	AS ON 06/12/22	FOR THE PERIOD	DEDUCTION	TOTAL	AS ON 31/03/2023	AS ON 06/12/2022
FURNITURE	6.23	22.38		28.61	7.80	1.40	0.00	9.20	19.41	0.00
OFFICE BUILDING	0.00	47.00		47.00	0.00	0.99	0.00	0.99	46.01	0.00
OFFICE EQUIPMENTS	4.07	10.95		15.02	1.78	1.24	0.00	3.02	12.00	0.00
COMPUTERS	0.45	5.98		6.43	1.70	0.73	0.00	2.43	4.00	0.00
VEHICLE	2.21	2.03		4.24	0.02	0.38	0.00	0.40	3.84	0.00
TOTAL	12.96	88.34	0.00	101.30	11.29	4.74	0.00	16.04	85.26	0.00



MONO PHARMACARE LIMITED

Consolidated Notes on financial statements for the year ended 31st March, 2023

CIN: U24304GJ2022PLC136193

(Rs in Lakhs)

	As at March 31, 2023
<u>NOTE 10 :- NON-CURRENT INVESTMENTS</u>	
Investment in Partnership firms	0.00
Fdr With Bank Of India	57.34
	57.34
<u>NOTE 11 :- STATEMENT OF DEFERRED TAX ASSET/LIABILITIES</u>	
Deferred Tax Assets	
on account of Depreciation on Fixed Assets	0.58
on account of Provision for Gratuity	0.66
on account of Other expense	4.25
	5.49
<u>NOTE 12 :- STATEMENT OF INVENTORIES</u>	
Stock in trade	3268.61
	3268.61
<u>NOTE 13 :- STATEMENT OF TRADE RECEIVABLES</u>	
<u>Unsecured, Considered Good</u>	
Over six months from the due date	436.84
Others	1750.23
	2187.07
<u>NOTE 14 :- STATEMENT OF CASH AND CASH EQUIVALENT</u>	
Cash in Hand	19.17
<u>Balances with Banks</u>	
Balances in Current Accounts	8.36
Fixed / Recurring Deposit with Bank	14.24
Total	41.77
<u>NOTE 15 :- STATEMENT OF SHORT TERM LOANS AND ADVANCES</u>	
Security Deposits	3.18
Advance to Suppliers	204.43
Other advances	327.77
Total	535.37
<u>NOTE 16 :- Other Current Assets</u>	
IPO Expenses	1.50
Advances to Employees	5.24
Balance with Revenue Authorities	72.58
Total	79.32




MONO PHARMACARE LIMITED	
Consolidated Notes to and forming part of statement of Profit and Loss for the year ended March 31, 2023	
CIN: U24304GJ2022PLC136193	
(Rs in Lakhs)	
Particulars	From 06/12/2022 to 31/03/2023
<u>NOTE 17 :- STATEMENT OF REVENUE FROM OPERATIONS</u>	
<u>Sales</u>	
- Sale of Goods	2699.05
Total	2699.05
<u>NOTE 18 :- STATEMENT OF OTHER INCOME</u>	
Commission Income	0.13
Interest on Fixed deposit	0.26
Profit From Partnership firm	16.98
Sales Cum Promotion Income	5.85
Misc. Income	0.03
Total	23.26
<u>NOTE 19 :- STATEMENT OF PURCHASE OF TRADED GOODS</u>	
<u>Purchases</u>	
Purchase of Goods	3437.91
Less: Purchase return	18.73
Total	3419.18
<u>NOTE 20 :- STATEMENT OF INCREASE/(DECREASE) IN STOCK</u>	
Closing Stock	3268.61
Opening Stock	2252.58
Total	-1016.03
<u>NOTE 21 :- STATEMENT OF EMPLOYEE BENEFITS EXPENSES</u>	
Salary Expenses	46.19
Director/Partner Remuneration	24.60
Staff Welfare Expenses	0.83
Gratuity	2.63
ESI	0.98
Provident fund	2.93
	78.17
<u>NOTE 22 :- STATEMENT OF FINANCE COST</u>	
Interest Paid	72.50
Bank Charges	3.07
Processing Fees	1.53
	77.10



MONO PHARMACARE LIMITED**Consolidated Notes to and forming part of statement of Profit and Loss for the
year ended March 31, 2023****CIN: U24304GJ2022PLC136193****(Rs in Lakhs)**

Particulars	From 06/12/2022 to 31/03/2023
<u>NOTE 23 :- STATEMENT OF OTHER EXPENSES</u>	
Audit Fees	2.50
Business Promotion Expenses	8.28
Consultancy Expenses	1.49
Conveyance Expenses	6.26
Charity Expenses	2.70
Cylinder Charges	0.47
Electricity Expenses	0.78
Interest On Tds	0.02
Miscellaneous Expenses	0.52
Professional fees	3.25
Rates and Taxes	21.24
Legal Expenses	0.90
Loss on sale Fixed Assets	0.15
Telephone Expenses	0.46
Office Expenses	2.13
Packing Expenses	1.62
Postage & Courier Expenses	1.34
Printing & Stationery	3.49
Rent Expenses	4.41
Repairs & Maintence	0.19
ROC Exp	0.15
Software Expenses	1.09
Transportation Expenses	0.50
Travelling Expenses	2.24
	66.20



MONO PHARMACARE LIMITED

Note 1: Significant Accounting policies to the Financial Statements

Note 1.1: Corporate Information:

The Company was originally formed at Partnership Firm in the name and style of **M/s. Mono Chemist**. The firm was converted from Partnership firm into Limited Company with the name of **Mono Pharmacare Limited** with effect from 17th October, 2022 vide CIN U24304GJ2022PLC136193. The Company is engaged in the business of distribution of Pharmaceutical items.

Place of business:

The place of business of the Company is at 1A, Krinkal Apartment Opp. Mahalaxmi Temple, Paldi Ahmedabad Gujarat 380007.

Note 1.2: Significant Accounting Policies:

The significant accounting policies followed by the company are stated as below:

i. **Basis of Basis of accounting and preparation of consolidated financial statements:**

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles (GAAP) in India under the historical cost convention on accrual basis and in accordance with Accounting Standards prescribed under section 133 of the companies Act, 2013.

The consolidated financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of financial statements are consistent with those followed in the previous year. In the opinion of the Management, based on the analysis of the significant transactions at subsidiary, no material adjustments are required to be made to comply with group accounting policies / Indian GAAP.

Subsidiaries

Sr. No.	Name of the entities acquired	% of capital acquired
1	Ahmedabad Medical Corporation	99.00%
2	Supal Distributors LLP	99.00%



ii. Principles of consolidation


1. The Financial statements of the company and its Subsidiary firm combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, incomes and expenses, after eliminating material intragroup balances and intra-group transactions resulting in unrealized profits or losses in accordance with Accounting Standard-21 (AS21) "Consolidated Financial Statements".
2. As far as possible, the consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances and appropriate adjustments are made to the financial statements of the subsidiary firm when they are used in preparing the consolidated financial statements that are presented in the same manner as the Company's separate financial statements.
3. The difference between the cost of investment in the subsidiary firm over the net assets at the time of acquisition of shares in the joint ventures is recognized in the financial statements as Goodwill or Capital Reserve as the case may be.

iii. System of accounting and use of estimates:

- I. The Company follows the mercantile system of accounting and recognizes income & expenditure on an accrual basis except in case of significant uncertainties.
- II. Financial statements are prepared under the historical cost convention. These costs are not adjusted to reflect the impact of changing value in the purchasing power of money.
- III. Estimates and assumptions used in the preparation of the financial statements and disclosures are based upon management's evaluation of the relevant facts and circumstances as of the date of the financial statements, which may differ from the actual results at a subsequent date.

iv. Property, Plant and Equipment

- a. Fixed assets are carried at cost of acquisition less accumulated depreciation.
- b. The cost of fixed assets comprises the purchase price (net of rebates and discounts) and any other directly attributable costs of bringing the assets to their working condition for their intended use.



v. Depreciation:

- a. Depreciation on fixed assets is being provided on Written down value method as per the useful life prescribed in Schedule II of the Companies Act, 2013.
- b. Depreciation in respect of addition to fixed assets is provided on pro-rata basis from month to month in which such assets acquired/installed.
- c. Depreciation on fixed assets sold, discarded or demolished during the year is being provided at their respective rate upto the month in which such assets are sold, discarded or demolished.

vi. Investments

Investments are Long-term, unless stated otherwise and are stated at cost except where there is diminution in value other than temporary, in which case a provision is made to the carrying value to recognize the diminution.

vii. Taxation:

- a. Current tax:

Provision for current tax is made on the estimated taxable income at the rate applicable to the relevant assessment year.

- b. Deferred tax:

Deferred tax charge or benefit reflects the tax effects of timing differences between accounting income and taxable income, which originate during the year but reverse in subsequent years.

The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantially enacted by the balance sheet date.

viii. Revenue Recognition:

- Sales of pharmacy products are exclusive of GST and are stated net of discounts. Sale of pharmacy products is recognized when risk and rewards of ownership of the products are passed on to the customers, which is generally on dispatch of goods. Returns against sales and price difference are recognized as and when ascertained and are netted from the amount of sales for the year.



ix. Borrowing Cost:

Borrowing costs include interest, amortization of ancillary costs incurred and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Costs in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the Statement of Profit and Loss over the tenure of the loan.

Borrowing costs, allocated to and utilized for qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalization of such asset is added to the cost of the assets.

Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

x. Current & Non-Current Classification:

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set-out in the Act. Deferred tax assets and liabilities are classified as non-current assets and non-current liabilities, as the case may be.

xi. Inventories:

Inventories are valued at the lower of cost (Generally determined on FIFO basis) and Net realizable value. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges.

xii. Provisions and Contingencies:

- a. A provision is recognised when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on management best estimates of the expenditure required to settle the obligation as at the balance sheet date. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate of each such obligation.
- b. A contingent liability is disclosed when there is a possible or present obligation that may, but probably will not require an outflow of



resources, unless the possibility of such outflow is remote.

- c. Contingent Assets are neither recognised nor disclosed.

xiii. Cash Flow Statement

The Cash Flow Statement is prepared by the indirect method set out in Accounting Standard 3 on Cash Flow Statements and presents the cash flows by operating, investing and financing activities of the Company.

Cash and Cash equivalents presented in the Cash Flow Statement consist of cash on hand and unencumbered bank balances and Fixed Deposit with the banks which are short term.


xiv. Earnings per Share:

Basic earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year. Diluted earning per share is computed by dividing the net profit after tax attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year as adjusted for the effects of all dilutive potential equity shares, if any.

25. During the year, the Company has acquired the running business of DLS Export, Proprietary concern of Mr Panilam Lakhtariya as on December 15th, 2022 of Rs.6,09,80,385/- and in consideration the Company has issued 50,81,699 number of Equity shares of Rs. 12 each.

26. During the Year, the Company has acquired the 99% capital each into partnership firm named as below:

Sr. No.	Name of the entities acquired	% of capital acquired	Date of acquisition	Amount paid
1	Ahmedabad Medical Corporation	99.00%	01/02/2023	Rs.9,99,000/
2	Supal Distributors LLP	99.00%	01/02/2023	Rs.99,900/



27. Related Parties Transactions

As per Accounting Standard 18, the disclosures of transactions with the related parties are as under:

A. Directors of the Company:

1. Panilam Shivilal Lakhatariya - Managing Director
2. Supal Panilam Lakhatariya - Director
3. Archit Shah - Executive Director
4. Mitul Sapara - Non - Executive Director
5. Chintan Trivedi - Independent director
6. Gaurang Vora - Independent director

B. Key Management Personnel:

1. Panilam Shivilal Lakhatariya Director
2. Supal Panilam Lakhatariya Director
3. Krupali R. Thakkar Company Secretary (w.e.f. Appointment date 26/12/2022)
4. Mrs. Neha Prajapati - Chief Financial Officer

C. Relatives of the Director/s:

1. Supal Panilam Lakhatariya Wife of Mr. Panilam Lakhatariya
2. Archit Shah Brother of Mrs. Supal Lakhatariya

D. Enterprise over which Directors is having significant influence:

1. Supal Medical & Wholesale LLP
2. Supal Pharma
3. R.B. Agencies
4. Supal Trading LLC
5. Stylemantraas Private Limited

D. Enterprise over which Directors is having significant influence:

1. Supal Medical & Wholesale LLP
2. Supal Pharma
3. R.B. Agencies
4. Supal Trading LLC
5. Stylemantraas Private Limited
6. Panilam Lakhatariya HUF


E. Subsidiaries Entities

1. Ahmedabad Medical Corporation,
2. Supal Distributors LLP


The following transactions were carried out with the related parties in the ordinary course of business (except reimbursement of actual expenses)

(Rupees in Lakhs)

Particulars	Nature of Transaction	For the period ended on 31/03/2023
A. Key Managerial Person		
1. Panilam Shivilal Lakhatariya	Remuneration	4.00




	Loan Taken	4.92
	Loan Repaid	4.92
	Share Allotment	866.29
2. Supal Panilam Lakhatariya	Remuneration	4.00
	Sales	0.00
	Loan repaid	1.01
	Share Allotment	194.35
	Loan Taken	34.18
	Loan Repaid	17.77
3. Archit Shah Current Capital	Remuneration	1.60
	Loan taken	0.20
	Share Allotment	0.05
4.Pallaviben Shah	Loan taken	0.20
	Share Allotment	0.05
5.Shardaben Lakhatariya	Loan taken	0.20
	Share Allotment	0.05
6.Shivam Chauhan	Loan taken	0.20
	Share Allotment	0.05
7.Shivlal Lakhatariya Current Capital	Loan taken	0.20
	Share Allotment	0.05
B. Subsidiaries		
1. Supal Distributors LLP		0.00
	Loan Repiad	0.00
	Sales	339.74
	Purchase	309.99
	Investment	0.99
	Profit Received from firm	8.88
2. Ahmedabad Medical Corporation	Sales	114.04
	Purchase	238.95
	Investment	176.99
	Profit Received from firm	9.69



C. Transactions with entities wherein Key Managerial Personnel have significant influence:		
1. Panilam Shivilal Lakhatariya HUF	Loan Taken	0.00
	Loan Repaid	4.92
2. Supal Pharma	Sales	256.81
	Purchase	137.35
3. Supal Medical & Wholesale LLP	Sales	171.66
	Purchase	138.96
4. RB Agencies(s)	Sales	8.78

Balance outstanding	Nature of Transaction	For the period ended on 31/03/2023
A. Key Managerial Person		
1. Panilam Lakhatariya	Loan from Director	0.00
2. Supal Lakhatariya	Loan from Director	204.01
3. Archit Shah	Loan from Director	0.20
4. Pallaviben Shah	Loan from Director	0.20
5. Shardaben Lakhatariya	Loan from Director	0.20
6. Shivam Chauhan	Loan from Director	0.20
7. Shivilal Lakhatariya	Loan from Director	0.20
B. Subsidiaries		
1. Supal Distributors LLP	Sales & Purchase	-0.84
	Investment	9.87
2. Ahmedabad Medical Corporation(S)	Sales & Purchase	81.78
	Investment	186.69
C. Transactions with entities wherein Key Managerial Personnel have significant influence:		
1. Panilam Shivilal Lakhatariya HUF	Loan	0.00
2. Supal Pharma	Sales	-29.00
3. Supal Medical & Wholesale LLP	Purchase	29.61
4. RB Agencies	Sales	-1.85



28. The particulars as required under the Accounting Standard-AS 15 of Employees Benefits are as under:

i. Defined Contribution Plan:

	For the year ended March 31,2023
Contribution to Employees Provident Fund	Rs.2,93,120/-

ii. Defined Benefit Plan:

The Company has made a gratuity provision as per the Payment of gratuity Act, 1972 of Rs. 2,62,789/- obtain from Pankaj Murawala, Labour Consultant and Advocate and has not obtain the actuarial valuation report from actuaries.

29. Dues to Micro & Small Enterprises:

Particulars	For the year ended March 31,2023
The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year	
- Principal amount due to micro and small enterprises	583.28
The amounts of payments made to micro and small suppliers beyond the appointed day during each accounting year.	-

On the basis of information and records available with the company, the above disclosures are made in respect of amounts due to the micro and small enterprises, who have registered with the relevant competent authorities.

30. Earnings per share:

The calculations of earnings per share (basic and diluted) are based on the earnings and number of shares as computed below:



	For the year ended March 31, 2023
Profit/(Loss) after Tax	Rs.69.57Lacs
Weighted no. of equity shares	9,831,464
Earnings per share	
- Basic	0.71
- Diluted	0.71

31. Deferred Taxation:

(Rs. in Lacs)

	Items of Timing Difference	Accumulated Deferred Tax (Asset) / Liability as on April 1, 2022	Charge/ (credit) for the year	Accumulated Deferred Tax (Asset)/ Liability as on March 31, 2023
Deferred Tax Assets				
i.	WDV of Depreciable assets	-	0.58	0.58
ii	Gratuity	-	0.66	0.66
iii	Other	-	4.25	4.25
Net Deferred Tax		-	5.49	5.49

32. Disclosures of Accounting Ratios:

DISCLOSURE OF ACCOUNTING RATIOS AND REASON FOR VARIANCE				
	Particulars	Formula for Computation	Measures (in times / percentage)	For the period ended on 31st March, 2023
A	Current Ratio	Current assets / Current liabilities	Times	2.20
B	Debt Equity Ratio	Debt / Net worth	Times	0.93
C	Debt Service Coverage Ratio	EBITDAE / (Finance costs + Principal repayment of borrowings within one year)	Times	0.08
D	Return on Equity	Profit after tax / Net worth	Percentage	5.20%
E	Inventory Turnover Ratio	Cost of goods sold / Average inventory	Times	0.74
F	Trade Receivable Turnover Ratio	[Revenue from Sales of products (including excise duty) + Sales of services] / Average gross trade receivables	Times	1.23
G	Trade Payable Turnover Ratio	Purchases / Average trade payables	Times	5.05
H	Net Capital Turnover Ratio	Revenue from operations / working capital	Times	0.90
I	Net Profit Ratio	Profit after tax / Revenue from operations	Percentage	2.56%
J	Return on Capital Employed (ROCE)	EBIT / Capital employed	Percentage	5.42%
K	Return on Investment (ROI)	Earning / Cost of Investment	Percentage	30.07%
Notes				
1	Debt = Non-current borrowings + Current borrowings			
2	Net worth = Paid-up share capital + Reserves created out of profit+ Security premium - Accumulated losses			
3	Cost of goods sold = Cost of materials consumed + Purchase of stock-in-trade + Changes in inventories of finished			
4	Purchase = Purchase of stock-in-trade + Purchase of Raw Material and packing material			
5	Working Capital = Current assets - Current liabilities			
6	EBIT = Earnings before Interest, tax and exceptional items			
7	Capital employed = Total equity + Non-current borrowings			




33. Debtors & Creditors balances are subject to confirmation. Adjustments, if any, will be made in the accounts on the receipt of such confirmations.

34. In the opinion of the Board, current assets, loans and advances have a value on realization at least equal to the amount at which they are stated in the accounts.

As per our attached report of even date

For and on behalf of the Mono Pharmacare Limited

**For Kumbhat & Co.
Chartered Accountants**


**Gaurang C. Unadkat
Partner
Membership No. 131708**


**Panilam S Lakhatariya
Chairman & Managing Director
DIN:07659275**

A. S. Shah
**Archit Shah
Director
DIN: 09737945**


**Neha C Prajapati
Chief Financial Officer**


**Krupali Thakkar
Company Secretary**

Place : Ahmedabad
Date : August 7th, 2023

Place : Ahmedabad
Date : August 7th, 2023

